Could a common blood pressure drug lower uric acid in kids with kidney problems?
NCT ID NCT05402397
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether losartan, a blood pressure medicine, can lower uric acid levels in children with proteinuric nephropathies (kidney disease with protein in urine). Forty children already taking enalapril were randomly assigned to receive either losartan or continue enalapril for 30 days, then switched after a washout period. Researchers measured uric acid in blood and urine to see if losartan made a difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Losartan potassium
What this could lead to
If it works, this could show that losartan helps manage uric acid levels in children with kidney disease, offering a potential additional treatment option.
What could go wrong
This is a small, early-phase study with only 40 children, and it focuses on a lab marker (uric acid) rather than long-term health outcomes. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URIC ACID NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HGNPE
CABA, Buenos Aires F.D., 1417, Argentina